SEC Form 4 · accession 0001209191-17-051472

aTYR PHARMA INC · LIFE

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Director

Period of report

Aug 31, 2017

Accepted (ET)

Sep 5, 2017 · 8:22 pm EDT

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0001339970

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I	Nature of ownership
Common Stock^F1,F2	Aug 31, 2017	P	94,336	$2.65	A	377,917	I	See Footnote
Common Stock	holding	—	—		—	40,440	D
Common Stock^F3	holding	—	—		—	721,814	I	See Footnote

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Warrant to Purchase Common Stock^F1,F2	$4.64	Aug 31, 2017	P	35,376	A	Aug 31, 2017	Dec 31, 2019	Common Stock	35,376	35,376	I

F1Represents shares acquired in a private placement pursuant to a Securities Purchase Agreement dated August 27, 2017 by and among the Company and select group of institutional and accredited investors named therein (the "Securities Purchase Agreement"). Pursuant to the terms of the Securities Purchase Agreement, investors purchased common stock units for $2.65 per common stock unit. Each common stock unit consisted of one share of the Company's Common Stock and a warrant to purchase 0.375 shares of the Company's Common Stock.
F2These shares are owned directly by Paul Schimmel Prototype PSP, Paul Schimmel Trustee, FBO Paul Schimmel. The Reporting Person is the sole owner of the Paul Schimmel Prototype PSP, Paul Schimmel Trustee, FBO Paul Schimmel, which was incorrectly reported as Paul R. Schimmel Prototype PSP on past Form 4s filed by the Reporting Person.
F3There shares are owned directly by Schimmel Revocable Trust U/A Dtd 9/6/2000. The Reporting Person and his spouse are trustees of the Schimmel Revocable Trust U/A Dtd 9/6/2000.